Musk "takes the goods" to promote (LLY.US) weight loss drug: Mounjaro has fewer side effects and better effectiveness.

Tesla, Inc. (TSLA.US) CEO Musk emphasized in a post on X platform on Wednesday that he prefers Lilly's competitor Mounjaro over Novo Nordisk A/S Sponsored ADR Class B's (NVO.US) weight loss therapy Ozempic. On Wednesday, Musk posted an article titled "Ozempic Santa" along with a picture of himself dressed as Santa Claus. When asked about the specific product he uses, Musk pointed out, "Technically, it's Mounjaro, but that sounds different." "Mounjaro seems to have fewer side effects and be more effective," he explained. It is understood that Mounjaro and Ozempic's generic names are tirzepatide and semaglutide, respectively, and both are glucagon-like peptide-1 (GLP-1) receptor agonists sold under the brand names Zepbond and Wegovy for weight loss. Musk has credited his weight loss to Wegovy. However, given Musk's strong support for GLP-1, he appears to disagree with the views of the US President-elect Trump's pick for Health Secretary, Robert F. Kennedy, who has long advocated for controlling diet rather than relying on drugs to combat obesity.